Author:
Fidanza Mario,Hibbert Julie,Acton Erica,Harbeson Danny,Schoeman Elizna,Skut Patrycja,Woodman Tabitha,Eynaud Adrien,Hartnell Lucy,Brook Byron,Cai Bing,Lo Mandy,Falsafi Reza,Hancock Robert E. W.,Chiume-Kayuni Msandeni,Lufesi Norman,Popescu Constantin R.,Lavoie Pascal M.,Strunk Tobias,Currie Andrew J.,Kollmann Tobias R.,Amenyogbe Nelly,Lee Amy H.
Abstract
AbstractNeonatal sepsis is a major cause of childhood mortality. Limited diagnostic tools and mechanistic insights have hampered our abilities to develop prophylactic or therapeutic interventions. Biomarkers in human neonatal sepsis have been repeatedly identified as associated with dysregulation of angiopoietin signaling and altered arachidonic acid metabolism. We here provide the mechanistic evidence in support of the relevance for these observations. Angiopoetin-1 (Ang-1), which promotes vascular integrity, was decreased in blood plasma of human and murine septic newborns. In preclinical models, administration of Ang-1 provided prophylactic protection from septic death. Arachidonic acid metabolism appears to be functionally connected to Ang-1 via reactive oxygen species (ROS) with a direct role of nitric oxide (NO). Strengthening this intersection via oral administration of arachidonic acid and/or the NO donor L-arginine provided prophylactic as well as therapeutic protection from septic death while also increasing plasma Ang-1 levels among septic newborns. Our data highlight that targeting angiogenesis-associated pathways with interventions that increase Ang-1 activity directly or indirectly through ROS/eNOS provide promising avenues to prevent and/or treat severe neonatal sepsis.
Funder
Canadian Institutes of Health Research
Publisher
Springer Science and Business Media LLC